Diabetes

By Heather Mack November 11, 2016
Israel-based DarioHealth, which makes a smartphone-connected blood glucose monitor, has made significant headway in the US, Australian and Canadian markets, seling 5,500 devices in the US this quarter and 8,500 worldwide. The company launched in the US in March, and quickly built up a customer base with more than 100 percent increase in growth by the second quarter. Coasting on that wave of new...
By Heather Mack November 9, 2016
A new tool to diagnose diabetes is in the works, and it’s a far cry from the often painful and invasive method of drawing blood. Researchers at the University of Oxford are developing a portable device, similar to breathalyzers used to detect blood alcohol level, that they believe can potentially diagnose diabetes non-invasively and monitor glucose levels. Head researchers Robert Peverall and his...
By Jonah Comstock November 9, 2016
Senseonics, the Germantown, Maryland-based company which went public in January and is working on a longterm implantable continuous glucose monitor, has submitted its PMA application to the FDA, President and CEO Tim Goodnow said on the company's third quarter earnings call last week. In addition, the company continues to work on a second generation device and its first pediatric clinical trial...
By Jonah Comstock October 24, 2016
Three bits of news this week from companies working on diabetes management offerings might be of interest to anyone interested in digital health.  First off, NovioSense, a Dutch company developing a smartphone-connected tear-based glucose sensor that sits in the lower eyelid, secured an undisclosed amount of new funding. The round included existing investors Health Innovations, Topfonds...
By Heather Mack October 13, 2016
The digital behavioral health coaching program from Omada Health has been shown to reduce overweight and obese seniors' risk of developing type 2 diabetes and heart disease by helping them lose weight and adopt healthier behaviors, according to a new study. Over a three-year span, researchers looked at 1,121 adults age 65 or older who had a baseline body mass index of 24 or higher, plus...
By Jonah Comstock October 11, 2016
Patients Pending, a London-based health startup founded by one of the co-creators of Skype and his brother, has announced that it will follow up its Timesulin insulin pen cap with a Bluetooth-connected insulin pen cap, which the company hopes will help create smart dosing systems for patients with Type 1 diabetes who don’t use an insulin pump.  “Our hypothesis has been, so much of the investment...
By Jonah Comstock October 6, 2016
Boston-based nonprofit T1D Exchange has announced its intentions to make a multi-million dollar investment in automated insulin delivery technologies, the smart algorithms that serve as the bridge between CGMs and insulin pumps in the quest to create an artificial pancreas. “Type 1 diabetes is a disease that, since the invention of artificial insulin back in 1921, still plagues us because...
By Jonah Comstock September 20, 2016
Ochsner Health System in New Orleans has catapulted itself into the front lines of hospital innovation in the last few years as an early Apple HealthKit adopter, with its in-house "O Bar" app store, and with an initially successful blood pressure monitoring trial, the details of which Chief Clinical Transformation Officer Richard Milani shared at MobiHealthNews' event in June. At the DPharm...
By Heather Mack July 26, 2016
San Francisco-based Omada Health, an online and mobile behavioral medicine company, announced today a partnership with the American Medical Association and a new customer, Utah-based Intermountain Healthcare system, which will offer Omada’s flagship diabetes prevention program (DPP), Prevent, to its patients. The Prevent program aims to reduce the number of adults who develop type 2 diabetes. All...
By Heather Mack July 22, 2016
An FDA advisory panel has voted in favor of recommending a change to the intended use of Dexcom’s G5 Continuous Glucose Monitor (CGM). The G5 had already been FDA-approved, but with limitations as an adjunctive device, meaning it could only be used for tracking and trending interstitial fluid gluocose concentrations rather than as a full replacement for a traditional fingerstick blood glucose...